Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

The Use of Progestogen in the Treatment of Metastatic Carcinoma of the Kidney and Uterine Body

Abstract

The effect of the progestogen medroxyprogesterone acetate on metastases from renal, endometrial and other tumours has been studied in 25 patients. Seven patients with renal and endometrial tumours had a useful response, pulmonary metastases and a large primary renal tumour showing the greatest effect. Bony metastases were unaffected by the drug and were treated by local radiotherapy. If a response occurred, it did so within 3 months.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Paine, C., Wright, F. & Ellis, F. The Use of Progestogen in the Treatment of Metastatic Carcinoma of the Kidney and Uterine Body. Br J Cancer 24, 277–282 (1970). https://doi.org/10.1038/bjc.1970.31

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/bjc.1970.31

Search

Quick links